MDT · News · 20261012N
Regulatory Approval Milestones
Medtronic plc · 2026-10-12 · Importance 38 · Surprise 42 · In source text
Medtronic achieved 96% U.S. reimbursement coverage for the VenaSeal system, reducing a stated adoption barrier for the vein-treatment platform. The company also received new CPT codes for the Altaviva and Symplicity Spyral systems and FDA clearance for ApexCut EM blades. Separate reporting cited new FDA and CE Mark approvals for cardiac-ablation technologies and permanent CPT codes for neuromodulation and renal-denervation procedures.
Key facts
- Medtronic received new CPT codes for Altaviva and Symplicity Spyral systems. source
- Medtronic received FDA clearance for ApexCut EM blades. source
- Medtronic received new FDA/CE approvals for cardiac ablation devices. source
- Analysts cited permanent CPT codes for neuromodulation and renal denervation procedures as secured by Medtronic. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Medtronic received new CPT codes for Altaviva and Symplicity Spyral systems. |
| revenue | positive | probable | — | Medtronic received FDA clearance for ApexCut EM blades. |
| revenue | positive | probable | — | Medtronic received new FDA/CE approvals for cardiac ablation devices. |